KIM-ANH DO to Leukemia, Myelomonocytic, Chronic
This is a "connection" page, showing publications KIM-ANH DO has written about Leukemia, Myelomonocytic, Chronic.
Connection Strength
0.758
-
Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Exp Hematol. 2022 11; 115:44-53.
Score: 0.154
-
MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma. 2022 12; 63(13):3154-3164.
Score: 0.154
-
Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia. Leukemia. 2022 08; 36(8):2097-2107.
Score: 0.152
-
Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia. Leuk Res. 2021 02; 101:106511.
Score: 0.138
-
LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents. Leuk Lymphoma. 2020 06; 61(6):1493-1499.
Score: 0.129
-
Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes. Leukemia. 2020 03; 34(3):872-881.
Score: 0.032